Astrazeneca moves to upstage Moderna in Covid-19 vaccines
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
Moderna reminds the markets of biotech’s dual purpose
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Lonza to do the heavy lifting for Moderna’s Covid-19 vaccine
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
The long path to an effective coronavirus vaccine
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
Big-caps join the coronavirus scramble
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Takeda’s dengue data spell more bad news for Sanofi
Takeda’s pivotal trial has suggested that TAK-003 could work in both dengue-naïve and previously infected patients, making Sanofi’s Dengvaxia look irrelevant.
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Bavarian’s chance to draw a line under oncology
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Neon and Neurotrope await signs of proof of concept
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
